Pricing & Reimbursement: Unlocking The Potential For ATMPs

Pressure is being applied to the ‘traditional’ healthcare reimbursement model. As novel therapies continue to propel towards commercialization, healthcare systems and manufacturers are being asked to embrace evidence-based pricing strategies to lessen the burden of upfront costs. Our panelists will discuss how stakeholders across the drug development continuum can work together to manage availability and affordability, while reducing patient-adverse outcomes for these life-saving treatments.

In this panel you will learn about:

• The current state of therapy pricing, reimbursement, and value demonstration
• Solutions for improving patient access
• How to better understand durability of effect and long-term data requests
• Shifting from rare to prevalent indications
• Understanding payer and HTA engagement in the US and EU markets